Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: A randomized, placebo-controlled, multiple fixed-dose trial

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1874-1888

  Locatelli, Francesco ^a   Dimkovic, Nada ^b   Spasovski, Goce ^c  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Chronic kidney disease; Colestilan; Dyslipidaemia; Hyperphosphataemia; MCI 196

Indexed keywords

CALCIUM; COLESTILAN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHORUS; PLACEBO; URIC ACID;

ABDOMINAL DISTENSION; ADVERSE OUTCOME; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHOLESTEROL METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; UPPER ABDOMINAL PAIN; VOMITING;

CHRONIC KIDNEY DISEASE; COLESTILAN; DYSLIPIDAEMIA; HYPERPHOSPHATAEMIA; MCI-196;

BILE ACIDS AND SALTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84884513775     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft064     Document Type: Article

References (32)

1. United States Renal Data System. USRDS 1997 annual data report: VI causes of death. Am J Kidney Dis 1997; 30: S107-S117
2. Vanholder R, Massy Z, Argiles A et al. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
3. Collins AJ, Li S, Ma JZ et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38(4 Suppl 1): S26-S29
4. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41 (4 Suppl 3): I-IV, S1-91
5. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
7. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
8. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
10. Guérin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
11. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
12. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; S1-S130
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
14. Cheung AK. Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 2009; 4: S95-S101
15. Baigent C, Landray MJ, Reith C; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
16. Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005; 20: 424-430
17. Date T, Shigematsu T, Kawashita Y et al. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18 (Suppl 3): iii90-iii93
18. Locatelli F, Dimkovic N, Pontoriero G et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebocontrolled study. Nephrol Dial Transplant 2010; 25: 574-581
19. Nakaya N, Goto Y; MCI-196 Study Group. Colestilan: a new bile acids sequestrant resin. A review of its clinical study in hypercholesterolaemia in Japan. Atherosclerosis 2000; 151: 134-135
20. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
21. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
22. Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7: 487-493
23. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
24. Wanner C, Krane V, März W; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
25. Fellström BC, Jardine AG, Schmieder RE; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
26. Grundy SM, Cleeman JI, Merz CN; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732
27. Sturm G, Lamina C, Zitt E et al. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature. PLoS One 2011; 6: e20093
28. Neri L, Rocca Rey LA, Lentine KL et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58: 398-408
29. Suliman ME, Johnson RJ, García-López E et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48: 761-771
30. Latif W, Karaboyas A, Tong L et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011; 6: 2470-2477
31. Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008; 52: 136-144
32. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008; 324: 1-7